Phencyclidine alters regional concentrations of neuropeptide Y and peptide YY in rat brain

Biological Psychiatry

Volumn 40, Issue 12, 1996, Pages 1246-1254

  Sakai, Kazuo ^a,b   Maeda, Kiyoshi ^b   Okuyama, Shigeru ^c   Tanaka, Chikako ^b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hyogo Institute for Aging Brain and Cognitive Disorders   (Japan)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

cerebral cortex; limbic system; neuropeptide Y; peptide YY; phencyclidine (PCP); striatum

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID; NEUROPEPTIDE Y; PHENCYCLIDINE;

ANIMAL TISSUE; ARTICLE; BRAIN; IMMUNOREACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030589462     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00608-7     Document Type: Article

References (41)

1. Aniline O, Pitts FN (1982): Phencyclidine (PCP): A review and perspectives. Crit Rev Toxicol 10:145-157.
2. Bakker CB, Amini FB (1961): Observations on the psychotomimetic effects of sernyl. Compr Psychiatry 2:269-280.
3. Berrettini WH, Doran AR, Kelsoe J, Roy A, Pickar D (1987): Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1:81-83.
4. Bouchard P, Dumont Y, Fournier A, St.-Pierre S, Quirion R (1993): Evidence for in vivo interactions between neuropeptide Y-related peptides and sigma receptors in the mouse hippocampal formation. J Neurosci 13:3926-3931.
5. Csernansky JG, Murphy GM, Faustman WO (1991): Limbic/ mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 30:383-400.
6. Davies BM, Beech HR (1960): The effect of 1-arylcyclohexilamine (Sernyl) on twelve normal volunteers. J Ment Sci 106:912-924.
7. Ekman R, Wahlestedt C, Böttcher G, Sundler F, Hakanson R, Panula P (1986): Peptide YY-like immunoreactivity in the central nervous system of the rat. Regul Pept 16:157-168.
8. Engber TM, Boldry RC, Kuo S, Chase TN (1992): Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 581:261-272.
9. Flood JF, Hernandez EN, Morley JE (1987): Modulation of memory processing by neuropeptide Y. Brain Res 421:280-290.
10. Frederiksen SO, Ekman R, Gottfries C-G, Widerlöv E, Jonsson S (1991): Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83:273-277.
11. Gao XM, Shirakawa O, Du F, Tamminga CA (1993): Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 241:7-15.
12. Heilig M, Widerlöv E (1990): Neuropeptide Y: An overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illness. Acta Psychiatr Scand 82: 95-114.
13. Heilig M, Wahlestedt C, Widerlöv E (1988): Neuropeptide Y (NPY)-induced suppression of activity in the rat: Evidence for NPY receptor heterogeneity and for interaction with alpha-adrenoceptors. Eur J Pharmacol 157:205-213.
14. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
15. Kakigi T, Maeda K (1992): Effects of serotonergic agents on regional concentrations of somatostatin and neuropeptide Y-like immunoreactivities in rat brain. Brain Res 599:45-50.
16. Kaneda H, Maeda K (1994): Alteration in regional brain neuropeptides following intracerebroventricular infusion of excitotoxins in rats. Biol Psychiatry 36:103-109.
17. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Maeda K, Kawata E, Sakai K, Chihara K (1993): Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide Y in rat brain. Eur J Pharmacol 233:227-235.
19. Maeda K, Yasuda M, Kaneda H, Maeda S, Yamadori A (1994): Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides 27:323-332.
20. Massari VJ, Chan J, Chromwell BM, O'Donohue TL, Oertel WH, Pickel VM (1988): Neuropeptide Y in the rat nucleus accumbens: Ultrastructural localization in aspiny neurons receiving synaptic input from GABAergic terminals. J Neurosci Res 19:171-186.
21. Midgley LP, Bush LG, Gibb JW, Hanson GR (1992): Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen. Brain Res 593:89-96.
22. Midgley LP, Bush LG, Gibb JW, Hanson GR (1993): Differential regulation of neuropeptide Y systems in limbic structures of the rat. J Pharmacol Exp Ther 267:707-713.
23. Monnet FP, Debonnel G, Fournier A, Montigny C (1992): Neuropeptide Y potentiates the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus II. J Pharmacol Exp Ther 263:1219-1225.
24. Ogawa S, Okuyama S, Araki H, Nakazawa A, Otomo S (1994): A rat model of phencyclidine psychosis. Life Sci 55:1605-1610.
25. Palkovits M, Brownstein MJ (1988): Maps and Guide to Microdissection of the Rat Brain. New York: Elsevier.
26. Peters J, Von Kammen DP, Gelernter J, Yao J, Shaw D (1990): Neuropeptide Y-like immunoreactivity in schizophrenia: Relations with clinical measures. Schizophr Res 3:287-294.
27. Quirion R, Dimaggio DA, French ED, et al (1984): Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides 5:967-973.
28. Raja SN, Guyenet PG (1980): Effects of phencyclidine on the spontaneous activity of monoaminergic neurons. Eur J Pharmacol 63:229-233.
29. Riviere PJM, Rao RK, Pascaud X, Junien L, Porreca F (1993): Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum. J Pharmacol Exp Ther 264:1268-1274.
30. Roman FJ, Pascaud X, Duffy O, Vauche D, Martin B, Junien JL (1989): Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites. Eur J Pharmacol 174: 301-302.
31. Roman FJ, Pascaud X, Duffy O, Junien JL (1991): N-Methyl-D-aspartate receptor complex modulation by neuropeptide Y and peptide YY rat hippocampus in vitro. Neurosci Lett 122:202-204.
32. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelem D (1959): Comparison of Sernyl with other drugs. Arch Gen Psychiatry 1:651-656.
33. Sakai K, Maeda K, Kaneda H, Chihara K (1995): Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides 29:157-161.
34. Stanley BG, Leibowitz SF (1984): Neuropeptide Y: Stimulation of feeding and drinking by injection into the paraventicular nucleus. Life Sci 35:2635-2642.
35. Tam SW, Mitchell KN (1991): Neuropeptide Y and peptide YY do not bind to brain and phencyclidine binding sites. Eur J Pharmacol 193:121-122.
36. Tamminga CA, Thaker GK, Buchanan R, et al (1992): Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530.
37. Tamminga CA, Tanimoto K, Kuo S, et al (1987): PCP-induced alterations in cerebral glucose utilization in rat brain. Synapse 1:497-504.
38. Tanii Y, Nishikawa T, Umino A, Takahashi K (1990): Phencyclidine increased extracellular dopamine metabolites in rat medial frontal cortex as measured by in vivo dialysis. Neurosci Lett 112:318-323.
39. Tatemoto K, Carlquist M, Mutt V (1982): Neuropeptide Y - A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296:659-660.
40. Widerlöv E, Lindström LH, Wahlestedt C, Ekman R (1988): Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22:69-79.
41. Zukin SR, Temple A, Gardner EL, Zukin RS (1984): Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 294:174-177.